Pharma Stocks Near Record Highs as Tech Selloff Spurs Safety Trade
AbbVie, Eli Lilly, and Gilead Sciences surged toward all-time highs as investors rotated out of battered tech shares into defensive healthcare plays.
A pronounced rotation away from high-flying technology stocks propelled major pharmaceutical names toward record territory, underscoring how quickly market sentiment can shift when risk appetite fades. Shares of AbbVie, Eli Lilly, and Gilead Sciences all closed near all-time highs, benefiting from the same investor anxiety that punished growth-oriented tech positions.
The dynamic reflects a classic defensive pivot: when traders grow uneasy about stretched valuations or broader economic uncertainty, large-cap pharma tends to attract capital because its revenue streams are tied to healthcare demand rather than discretionary consumer spending or interest-rate-sensitive growth projections. In that sense, the pharmaceutical sector functions as a kind of shock absorber within diversified portfolios.
Read more Two Stocks Outpacing the Magnificent Seven in 2025 →
What makes this particular rotation notable is its timing. Tech stocks have enjoyed an extended period of dominance, driven largely by artificial intelligence enthusiasm, meaning the selloff represents a meaningful, if potentially temporary, reassessment of where risk-adjusted returns can be found. Pharma stocks, by contrast, carry the appeal of relatively predictable earnings and, in several cases, robust dividend profiles that become more attractive when equity volatility rises.
Whether this rotation proves durable will depend on the underlying cause of the tech weakness. If selling pressure reflects a broader de-risking rather than a sector-specific correction, defensive trades in healthcare and consumer staples could sustain momentum. If it amounts to a short-term profit-taking episode, fast-money flows may quickly reverse course and return to technology names once sentiment stabilizes.
For now, the surge in names like AbbVie, Eli Lilly, and Gilead signals that investors are, at minimum, hedging their bets — treating pharmaceutical equities as a port in an increasingly choppy market. Continue reading at MarketWatch.com
